Growth Hormone Releasing Peptides: Research Compound Overview

Growth hormone releasing compounds studied in laboratory research are classified into three distinct structural categories based on their receptor interactions and molecular architecture. GHRH (Growth Hormone Releasing Hormone) analogs bind the GHRH receptor (GHRH-R), a Class B G-protein coupled receptor, mimicking the endogenous 44-amino acid hormone. GHRPs (Growth Hormone Releasing Peptides) interact with the ghrelin receptor (GHS-R1a), a distinct pharmacological target. Non-peptide GH secretagogues like MK-677 also target GHS-R1a but feature small-molecule rather than peptide structures. According to a 2019 review in Endocrine Reviews, over 35 synthetic GH-releasing compounds have been characterized in the published literature [1].

The pharmacological distinction is critical for analytical characterization: GHRH analogs typically contain 29-44 amino acid residues with molecular weights above 3,000 Da, while GHRPs are hexapeptides or smaller with molecular weights below 1,000 Da. This size difference fundamentally affects chromatographic behavior, ionization in mass spectrometry, and appropriate analytical method selection. Research published in the Journal of Chromatography B found that GHRH analogs require gradient elution times approximately 2.3x longer than GHRPs under standard RP-HPLC conditions [2].

GHRH analogs are modified versions of endogenous growth hormone releasing hormone (GHRH 1-44). Sermorelin, the shortest clinically characterized analog, consists of the first 29 amino acids of GHRH (GHRH 1-29) with a molecular weight of 3,357.9 Da and the sequence Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2. The C-terminal amidation is essential for biological activity and represents a key quality marker in analytical testing.

CJC-1295 exists in two research forms: CJC-1295 without DAC (also known as Modified GRF 1-29) and CJC-1295 with DAC (Drug Affinity Complex). Modified GRF 1-29 has a molecular weight of 3,367.9 Da and incorporates four amino acid substitutions at positions 2 (D-Ala), 8 (Gln), 15 (Ala), and 27 (Leu) relative to native GHRH 1-29. These substitutions increase resistance to enzymatic degradation by DPP-IV, extending the compound's stability in solution. The DAC variant adds a maleimidopropionic acid-lysine linker conjugated to an albumin-binding moiety, increasing the total molecular weight to approximately 3,647 Da for the peptide portion. Published research in Growth Hormone & IGF Research reported that the DAC modification extends the in vitro serum stability from approximately 7 minutes to over 8 days [3].

Growth Hormone Releasing Peptides are synthetic hexapeptides and modified oligopeptides that interact with the GHS-R1a (ghrelin) receptor. GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) has a molecular weight of 873.0 Da and was among the first synthetic GHS-R1a ligands characterized in laboratory research. The inclusion of two D-amino acids (D-Trp at position 2 and D-Phe at position 5) confers protease resistance. GHRP-2 (D-Ala-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2) at 817.9 Da features a beta-naphthylalanine substitution that published binding studies indicate results in approximately 2-fold higher receptor affinity compared to GHRP-6 [4].

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a pentapeptide with a molecular weight of 711.9 Da. Its distinguishing structural feature is the N-terminal aminoisobutyric acid (Aib) residue, a non-proteinogenic amino acid that restricts backbone flexibility. Published selectivity studies in the European Journal of Endocrinology demonstrated that Ipamorelin shows high selectivity for GHS-R1a with minimal cross-reactivity at ACTH or prolactin-releasing pathways, making it analytically distinct in receptor binding assays [5]. The compound appears as a white lyophilized powder with greater than 98% purity achievable by standard solid-phase peptide synthesis methods.

MK-677 (Ibutamoren) is a non-peptide spiropiperidine compound with the molecular formula C27H36N4O5S and a molecular weight of 528.7 Da. Unlike peptide-based GHS-R1a ligands, MK-677 is orally bioavailable due to its small-molecule structure. Its chemical name is 2-amino-2-methyl-N-[1-(1-methylsulfonylspiro[indoline-3,4-piperidine]-1-yl)-1-oxo-3-(phenylmethoxy)propan-2-yl]propanamide. Published pharmacokinetic data in the Journal of Clinical Endocrinology & Metabolism reported an oral bioavailability exceeding 60% in preclinical models [6]. As a non-peptide compound, MK-677 requires different analytical approaches: LC-MS/MS rather than peptide-specific HPLC methods, and its identity is confirmed by molecular ion [M+H]+ at m/z 529.7 rather than by amino acid sequencing.

Analytical characterization of GH-releasing research compounds requires method selection appropriate to the compound class. For peptide-based compounds (Sermorelin, CJC-1295, GHRPs, Ipamorelin), reversed-phase HPLC (RP-HPLC) with C18 columns remains the gold standard for purity determination. ICH guideline Q6B recommends reporting purity as the percentage of the main peak area relative to total integrated peak area, with research-grade peptides typically requiring at least 95% purity [7]. USP Chapter 621 specifies method validation parameters including system suitability criteria of 2.0% RSD or less for replicate injections.

Mass spectrometric identity confirmation uses ESI-MS or MALDI-TOF depending on molecular weight. For peptides below 2,000 Da (GHRPs, Ipamorelin), ESI-MS provides superior resolution with [M+H]+ and [M+2H]2+ ions readily observable. For larger GHRH analogs, MALDI-TOF with sinapinic acid or CHCA matrix is preferred due to simplified charge state distributions. A 2021 study in Analytical Chemistry reported that LC-MS/MS with multiple reaction monitoring (MRM) can detect impurities at levels below 0.05% in synthetic peptide preparations, approximately 10x more sensitive than UV-based HPLC detection [8].

Amino acid analysis (AAA) provides orthogonal identity and quantity confirmation. Hydrolysis with 6N HCl at 110C for 24 hours followed by ion-exchange chromatography or pre-column derivatization (AccQ-Tag, OPA) quantifies individual amino acid content. For compounds containing D-amino acids (GHRP-6, GHRP-2, Ipamorelin), chiral chromatography or Marfey reagent derivatization is necessary to confirm correct stereochemistry — a critical quality attribute not detectable by standard RP-HPLC.

Lyophilized GH-releasing peptides demonstrate varying stability profiles depending on their structural features. Published stability data indicates that lyophilized Sermorelin stored at -20C under desiccated conditions maintains greater than 95% purity for at least 24 months [9]. The methionine residue at position 27 in native Sermorelin is susceptible to oxidation, making inert atmosphere (nitrogen or argon) storage essential. CJC-1295 variants with their DPP-IV-resistant substitutions show improved solution stability compared to native GHRH sequences.

For reconstituted solutions, GHRPs (GHRP-6, GHRP-2, Ipamorelin) demonstrate superior aqueous stability compared to GHRH analogs due to their smaller size and D-amino acid content. A 2020 forced degradation study published in the Journal of Pharmaceutical Sciences found that GHRP-6 solutions at pH 7.0 retained greater than 90% purity after 30 days at 4C, while Sermorelin solutions showed approximately 15% degradation under identical conditions [10]. All reconstituted peptide solutions should be stored at 2-8C, protected from light, and used within timeframes validated for the specific compound.

MK-677, as a small-molecule compound, shows distinct stability behavior. Its solid form is stable at room temperature (15-25C) for extended periods when protected from moisture. The sulfone moiety is resistant to oxidative degradation under standard storage conditions. Solutions in DMSO are stable for at least 6 months at -20C according to published analytical data.

GHRH analogs are 29-44 amino acid peptides derived from endogenous growth hormone releasing hormone that bind the GHRH receptor (GHRH-R). GHRPs are synthetic hexapeptides or pentapeptides containing D-amino acids that bind the ghrelin receptor (GHS-R1a). The two classes differ in molecular weight by approximately 4-5 fold, use distinct receptor pathways, and require different analytical methods for characterization. GHRH analogs typically have molecular weights above 3,000 Da while GHRPs range from 711-873 Da.

The Drug Affinity Complex (DAC) adds a maleimidopropionic acid-lysine linker to CJC-1295, increasing its molecular weight by approximately 280 Da for the peptide-linker portion. Analytically, DAC-modified CJC-1295 shows a shifted retention time on RP-HPLC due to increased hydrophobicity from the linker, and the DAC moiety produces characteristic fragment ions in MS/MS that distinguish it from the non-DAC variant. The conjugation efficiency can be assessed by monitoring unreacted peptide and free linker peaks.

MK-677 is a non-peptide spiropiperidine compound (MW 528.7 Da) that lacks amide bonds, amino acid residues, and peptide-characteristic UV absorption. It cannot be analyzed by amino acid analysis or peptide-specific HPLC methods. Instead, standard small-molecule LC-MS/MS with C18 reversed-phase chromatography and ESI ionization is used, with identity confirmed by molecular formula (C27H36N4O5S) and characteristic fragmentation pattern rather than sequence analysis.

Research-grade GH-releasing peptides are typically characterized using ICH Q6B guidelines adapted for synthetic peptides. Purity by RP-HPLC should be at least 95% (main peak area percentage), with individual related impurities below 1.0% and total impurities below 5.0%. Identity is confirmed by mass spectrometry (observed MW within 0.1% of theoretical), and peptide content is determined by amino acid analysis or nitrogen content measurement. USP Chapter 1057 provides additional guidance on biotechnology-derived compound characterization.

D-amino acid stereochemistry in GHRPs (D-Trp and D-Phe in GHRP-6, D-Ala and D-Phe in GHRP-2, D-2-Nal in Ipamorelin) is confirmed using chiral analysis methods. Marfey reagent (FDAA) derivatization followed by RP-HPLC separates D and L enantiomers of individual amino acids after acid hydrolysis. Alternatively, chiral HPLC columns (Chirobiotic T, Crownpak CR+) can resolve intact diastereomeric peptide impurities containing incorrect stereochemistry. The ICH Q6B specification recommends stereochemical identity as a release test parameter.

GHRH analogs are susceptible to several degradation pathways: (1) DPP-IV cleavage at the N-terminal Tyr-Ala bond in native sequences (mitigated by D-Ala substitution in CJC-1295), (2) methionine oxidation to methionine sulfoxide at Met-27 in Sermorelin, (3) asparagine deamidation at Asn-8, (4) C-terminal amide hydrolysis, and (5) aggregation through intermolecular beta-sheet formation at elevated concentrations. Monitoring these degradation products by RP-HPLC with UV detection at 214 nm is standard practice in stability studies.

Explore detailed chemical profiles and research guides for compounds discussed in this article:

• CJC-1295: Complete Research Guide → /learn/cjc-1295-no-dac
• GHRP-2: Complete Research Guide → /learn/ghrp-2-research-guide-chemical-profile
• GHRP-6: Complete Research Guide → /learn/ghrp-6-research-guide-chemical-profile
• Ipamorelin: Complete Research Guide → /learn/ipamorelin
• MK-677 (Ibutamoren): Complete Research Guide → /learn/mk-677-ibutamoren-research-guide-chemical-profile
• Sermorelin: Complete Research Guide → /learn/sermorelin-research-guide-chemical-profile

• Read more: GLP-1 Receptor Agonist Peptides: Research Compound Analysis → https://www.chemverify.com/learn/weight-loss-peptides-research
• Read more: Nootropic Peptides: Research Compound Profiles & Analysis → https://www.chemverify.com/learn/nootropic-peptides-overview
• Read more: Peptide Mimetics: Non-Peptide Analogs in Research → https://www.chemverify.com/learn/peptide-mimetics-overview
• Read more: Tissue Repair Peptides: Research Compounds & Analytical Profiles → https://www.chemverify.com/learn/healing-peptides-research-overview